Positive News SentimentPositive NewsNASDAQ:AVTX Avalo Therapeutics (AVTX) Stock Price, News & Analysis $4.94 +0.10 (+2.07%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$4.98 +0.04 (+0.81%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Avalo Therapeutics Stock (NASDAQ:AVTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Avalo Therapeutics alerts:Sign Up Key Stats Today's Range$4.76▼$5.0250-Day Range$3.59▼$5.0452-Week Range$3.39▼$16.00Volume554,180 shsAverage Volume63,499 shsMarket Capitalization$53.50 millionP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingBuy Company Overview Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland. Read More Avalo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreAVTX MarketRank™: Avalo Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 354th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAvalo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvalo Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Avalo Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Avalo Therapeutics are expected to grow in the coming year, from ($19.07) to ($4.70) per share.Price to Book Value per Share RatioAvalo Therapeutics has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Avalo Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.97% of the float of Avalo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvalo Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avalo Therapeutics has recently increased by 78.68%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvalo Therapeutics does not currently pay a dividend.Dividend GrowthAvalo Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.97% of the float of Avalo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvalo Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avalo Therapeutics has recently increased by 78.68%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment1.87 News SentimentAvalo Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Avalo Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 2 people have added Avalo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Avalo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.03% of the stock of Avalo Therapeutics is held by insiders.Percentage Held by Institutions87.06% of the stock of Avalo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avalo Therapeutics' insider trading history. Receive AVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AVTX Stock News HeadlinesAvalo Adds Dr. Rita Jain to Board as LOTUS Trial Advances4 hours ago | msn.comAvalo Therapeutics to Participate in Upcoming Investor ConferencesJune 23, 2025 | globenewswire.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.July 3 at 2:00 AM | Paradigm Press (Ad)Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of DirectorsJune 18, 2025 | globenewswire.comH.C. Wainwright upgrades Avalo Therapeutics stock to buyJune 4, 2025 | uk.investing.comAvalo Therapeutics Announces Leadership Change and Updates on AVTX-009 Phase 2 Trial for Hidradenitis SuppurativaMay 13, 2025 | nasdaq.comAVALO THERAPEUTICS Earnings Results: $AVTX Reports Quarterly EarningsMay 13, 2025 | nasdaq.comAvalo Therapeutics: Avalo Reports First Quarter 2025 Financial Results and Recent Business UpdatesMay 12, 2025 | finanznachrichten.deSee More Headlines AVTX Stock Analysis - Frequently Asked Questions How have AVTX shares performed this year? Avalo Therapeutics' stock was trading at $7.43 at the start of the year. Since then, AVTX shares have decreased by 33.5% and is now trading at $4.94. View the best growth stocks for 2025 here. How were Avalo Therapeutics' earnings last quarter? Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced its quarterly earnings results on Monday, May, 12th. The company reported ($1.25) earnings per share for the quarter, missing analysts' consensus estimates of ($1.07) by $0.18. When did Avalo Therapeutics' stock split? Avalo Therapeutics shares reverse split on the morning of Friday, December 29th 2023.The 1-240 reverse split was announced on Friday, December 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. How do I buy shares of Avalo Therapeutics? Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avalo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avalo Therapeutics investors own include Sangamo Therapeutics (SGMO), FuelCell Energy (FCEL), Canoo (GOEV), Aurora Cannabis (ACB), Agenus (AGEN), Meta Platforms (META) and Geron (GERN). Company Calendar Last Earnings5/12/2025Today7/03/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVTX CIK1534120 Webwww.avalotx.com Phone(410) 522-8707FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$30.00 High Stock Price Target$48.00 Low Stock Price Target$15.00 Potential Upside/Downside+507.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.13 million Net MarginsN/A Pretax Margin16,582.08% Return on Equity111.00% Return on Assets58.88% Debt Debt-to-Equity RatioN/A Current Ratio22.61 Quick Ratio22.61 Sales & Book Value Annual Sales$440 thousand Price / Sales121.59 Cash FlowN/A Price / Cash FlowN/A Book Value$12.80 per share Price / Book0.39Miscellaneous Outstanding Shares10,830,000Free Float10,500,000Market Cap$53.50 million OptionableNot Optionable Beta0.77 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:AVTX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.